ABSTRACT
O presente estudo tem como objetivo avaliar o efeito da administração do Zolazepam/Tiletamina nas funções cardiorrespiratórias e eletrocardiográficas em lobos-guará (Chrysocyon brachyurus) mantidos em cativeiro. Foram utilizados dez lobos-guará clinicamente saudáveis (seis machos e quatro fêmeas), com média de peso 23,5±3,5kg, e idade de 6,5±2,8 anos. Os lobos eram mantidos em cativeiro e foram capturados pelos tratadores, proporcionando o mínimo de estresse possível para avaliação dos parâmetros pré-anestésicos. Foram avaliadas frequência cardíaca e respiratória, temperatura retal, pressão arterial média e eletrocardiografia. Após coleta dos parâmetros fisiológicos e eletrocardiográficos pré-anestesia, foi administrada a dose de 5,1±0,7mg/kg de Zolazepam/Tiletamina intramuscular. Depois da anestesia, colocaram-se os eletrodos do eletrocardiograma nos membros torácicos e pélvicos. Os animais eram monitorados durante uma hora, sendo que, a cada 10 minutos, era realizado o registro dos valores eletrocardiográficos, assim como os valores dos parâmetros fisiológicos e cardiorrespiratórios. Os resultados mostraram alteração significativa na amplitude da onda P entre 10 a 50 minutos pós-anestesia. Frequência cardíaca (153±20bmp), frequência respiratória (29±6mpm), temperatura corporal (38,4±1oC), pressão arterial média (114±20mmHg) e as outras variáveis eletrocardiográficas não apresentaram alterações. O aumento da amplitude da onda P nos animais deste trabalho sugeriu um aumento atrial, oriundo de doenças cardíacas ou simplesmente pelo aumento da frequência cardíaca durante a contenção.
The aim of this study was to assess the effects of the anesthetic combination of Tiletamine/Zolazepam on the cardiorespiratory function and electrocardiographic profile in captive maned wolves (Chrysocyon brachyurus). Ten maned wolves were used in this study (6 males and 4 females). All animals were healthy, with an average body weight of 23.5±3.5kg, and age of 6.5±2.8years. The wolves were conditioned to be physically restrained by their keepers in order to minimize stress during assessment of pre-anesthetic parameters. Data on heart and respiratory rates, rectal temperature, mean arterial blood pressure and electrocardiography were collected. Pre-anesthetic physiological an eletrocardiographic parameters were collected before the administration of 5.1±0.73mg/kg Tiletamine/Zolazepam intramuscularly. Under anesthesia, electrocardiogram electrodes were placed on thoracic and pelvic limbs and eletrocardiographic data was recorded every 10 minutes for approximately one hour, totaling 6 electrocardiograms. Heart rate 153±20bmp, respiratory rate 29±6mpm, rectal temperature 38,4±1oC, mean arterial blood pressure 114±20mmHg, and the other electrocardiographic parameters did not change; however, the P wave amplitude changed from 10 to 50 minutes after anesthesia. The increase in the P wave on the animals in this study suggested an atrial increase, probably due to cardiac disease or just by increasing the heart rate during the capture.
Subject(s)
Animals , Arterial Pressure , Heart Rate , Respiratory Rate , Tiletamine/analysis , Wolves , Zolazepam/analysis , Anesthesia/veterinary , Electrocardiography/veterinaryABSTRACT
Schistosomes use proteinases to accomplish some tasks such as tissue penetration, tissue digestion for nutrition and evasion of host immune responses. The Cathepsin L is a cysteine proteinase of the papain superfamily detected in the gut lumen indicating that this enzyme contributes to the proteolysis of ingested hemoglobin. Due to these roles they play in the schistosome biology, proteolytic enzymes are considered potential targets to develop and direct anti-schistosomal therapies. In this work, the cDNA coding Cathepsin L1 of Schistosoma mansoni was cloned into the pAE vector that provides high-level expression of heterologous proteins in Escherichia coli. The recombinant protein was expressed as inclusion bodies, purified under denaturing conditions through nickel charged chromatography and used for experimental animal vaccination. ELISA was performed with the pooled sera. Although this protein showed to be immunogenic, mice immunized with three doses of recombinant protein plus aluminum hydroxide as adjuvant did not protect against S. mansoni infection.
Subject(s)
Animals , Female , Mice , Schistosomiasis mansoni/prevention & control , Escherichia coli Proteins/therapeutic use , VaccinesABSTRACT
A single-step chromatography on Matrex-Gel Blue A has been employed to obtain soluble extracts containing some of the most important antigens of Bordetella pertussis, pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (69-kDa outer membrane protein), fimbriae (FIM2 and FIM3) and adenylate cyclase (AC). Two supernatants, P19 (48.8 mg PT, 6.8 mg FHA, 17.3 mg AC, 13 mg FIM2 and 4.9 mg FIM33 per liter) and P21 (0.1 mg PT, 0.07 mg FHA, 0.46 mg FIM2 and 0.94 mg FIM3 per liter), resulting from bacteria grown in Stainer-Scholte medium, were submitted to chromatography. Fractions with the antigens were obtained after stepwise elution with 60 mM sodium phosphate buffer, pH 6.0; 50 mM Tris-HC1, pH 7.4; 50 mM Tris-HC1, pH 7.4/0.75 M MgCl2; 50mM Tris-HCl, pH 7.4/4 M MgCl2 and 4 M urea. Preparations from P19 (containing 4.05 µg PT, 8.14 µg FHA, 6.3 µg AC, 3.37 µg 69-kDA, 9.54 µg FIM2 and 2.23 µg FIM3) and P21 (with 0.175 µg PT, 0.28 µg PT, 0.28 µg FHA, 0.002 µg69-kDa, 0.005 µg FIM2 and 0.122 µg FIM3) were detoxified with glutaraldehyde and tested as an acellular pertussis vaccine. These products were non-toxic for mice and induced high levels of antibodies against purified pertussis antigens, as judged by ELISA